Kornimate/medical-research-clean huggingface dataset:
biomarkers in tissue samples from young patients with liver cancer

Conditions: Childhood Hepatoblastoma; Stage I Childhood Liver Cancer; Stage II Childhood Liver Cancer; Stage III Childhood Liver Cancer; Stage IV Childhood Liver Cancer

Summary: this research trial is studying biomarkers in tissue samples from young patients with liver cancer. studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer.

primary objectives: i. to identify biomarker signatures associated with hepatoblastoma subtypes (by microrna array profiling), and their potential correlation with liver developmental stages as well as outcome. ii. to correlate expression array data with copy number array data. secondary objectives: i. to carry out a focused sequencing interrogation of amplified or deleted genomic regions as well as genes in key cell pathways involved in embryonic development and/or stem cell signaling pathways for which preliminary data suggests involvement in the pathogenesis of hepatoblastoma. ii. to perform whole exome sequencing in a subset of tumors. outline: this is a multicenter study. archived tumor tissue samples are analyzed for hepatoblastoma and other liver tumor biomarkers by microrna array profiling and exome sequencing. results are then compared with patients' clinical data.

Eligibility criteria:
inclusion criteria: * diagnosis of hepatoblastoma or other liver cancer including the following subtypes: * pure fetal histology * transitional histology * small cell undifferentiated histology * participated on the children's oncology group (cog) clinical trials * available data and tumor samples
elupro antibiotic-eluting bioenvelope registry

Conditions: Cardiac Arrhythmias

Summary: a multi-center registry study evaluating participants who receive elupro antibiotic-eluting bioenvelope during cied implantation

this prospective, multi-center registry study will enroll up to 100 participants who will receive an elupro antibiotic-eluting bioenvelope during their cied procedure. participant data will be captured at several time points: screening/enrollment, day of surgical procedure, and at wound check (2-4 weeks) 3, 6, and 12 months post-surgery, as well as any unscheduled visits up to 12 months post-surgery. any follow-up visit can be completed via telephone/video if the participant is not scheduled to be seen in the office. patient-reported outcomes such as implant site pain and satisfaction questionnaires shall be administered to participants at each follow-up visit.

Eligibility criteria:
inclusion criteria: * patient is undergoing implantation of elupro with either a de novo cied implantation or has an existing cied and is undergoing cied replacement or upgrade. * patient is willing to comply with scheduled follow-up and study-related visits. * patient is 18 years of age or older at the time of enrollment. * patient agrees to provide written informed consent and use of phi. exclusion criteria: * patient has a prior history of cied infection, other prosthetic device infection, or endovascular infection, including endocarditis, in the past 12 months. * patient is exhibiting signs or symptoms consistent with any type of active infection (including but not limited to pneumonia, urinary tract, cellulitis, or bacteremia). * patient has stage 4 or 5 kidney disease (egfr \<30 ml/min). * patient requires long-term vascular access for any reason. * patient is undergoing implantation of a cied that does not fit completely into elupro, preventing closure of the bioenvelope to secure the cied. * patient is currently on chronic immunosuppressive agents or ≥20mg/day of prednisone or equivalent. * patient has known allergy to minocycline or rifampin or their derivatives, or any other known contraindications to the implantation of elupro. * patient is participating in another clinical study that could impact the outcome and documented pre-approval from the study sponsor has not been obtained. * female patient who is pregnant, or of childbearing potential and not on a reliable form of birth control. women of childbearing potential are required to have a negative pregnancy test within 7 days prior to device procedure.

Keywords: elupro cied envelope arrhythmia
demographics and clinical characteristics of paediatric intraocular inflammation in singapore

Conditions: Intraocular Inflammation in Children

Summary: data on demographics, etiology, clinical features, diagnosis, secondary complications, treatment and outcomes of intraocular inflammation in children aged 16 years and below that presented to uveitis clinic in singapore national eye centre (snec) from january 1989 to january 2017, will be retrieved and analyzed from the uveitis database retrospectively. the results will be compared with other published studies on different study populations.

data on demographics, etiology, clinical features, secondary complications, treatment and outcomes of intraocular inflammation in children aged 16 years and below that presented to uveitis clinic in singapore national eye centre (snec) from january 1989 to january 2017, will be retrieved from the uveitis database retrospectively. data on demographics, etiology, clinical features, diagnosis, secondary complications, treatment and outcomes will be analyzed using statistical software. the results will be compared with other published studies on different study populations. the results of this study will lead to an improved clinical practice with better treatment selections and an optimised monitoring protocol for follow up care for our paediatric patients with intraocular inflammation. this will lead to better clinical outcomes and prevention of serious sight threatening complications.

Eligibility criteria:
inclusion criteria: * children aged 16 years and below * clinical diagnosis of intraocular inflammation exclusion criteria: •children with ocular conditions other than intraocular inflammation.
effect of bifidobacterium breve b-3 on body fat in obese adults

Conditions: Obesity

Summary: comparison of a randomized, double-blind, and control-group study for the effect of oral ingestion of bifidobacterium breve b-3 on body fat reduction in obese adults

our aim is to investigate the effect of oral ingestion of bifidobacterium breve b-3 on body fat reduction in adults by a randomized, double-blind, and control-group study.

Eligibility criteria:
inclusion criteria: * bmi 27\~30 kg/m2 exclusion criteria: * within the last 6 months, severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage, etc.), heart disease(angina pectoris, myocardial infarction, heart failure, arrhythmia requiring treatment), or malignant diseases (however, although subjects have a history of cerebrovascular disease and heart disease, they can be included if their status are clinically stable) * patients with uncontrolled hypertension (blood pressure greater than 160/100 mmhg) * diabetic patients with poor glycemic control with a fasting blood glucose of 160 mg/dl or more * those who are treated with hypothyroidism or hyperthyroidism * creatinine levels: more than twice the normal upper limit * aspartate transaminase (ast), alanine transaminase (alt) levels: more than twice the normal upper limit * those complaining of severe gastrointestinal symptoms such as heartburn and indigestion * drugs that affect weight within the last month (absorption inhibitors and appetite suppressant, health food / supplements related to obesity improvement, psychiatric drugs, beta blockers, diuretics, birth control pills, steroids, female hormones) if you are taking * participated in the commercial obesity program within the last 3 months. * if you have participated or are planning to participate in another clinical trial within the past month if yes * alcohol abuser * smoking abstinence within 3 months * if they are pregnant or lactating or have a pregnancy plan during the clinical trial * those with allergic reactions to the constituent food * any person deemed inappropriate by the researcher for other reasons
effect of remote physiologic monitoring (rpm) on outcomes in copd patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this pre/post study was a retrospective analysis of unplanned hospitalization rates in a cohort of copd subjects started on remote physiologic monitoring (rpm) at a large, outpatient pulmonary practice. the study included all subjects with high healthcare utilization (≥1 hospitalization or emergency room visit in the prior year) who had elected to enroll in an rpm service for assistance with clinical management. additional inclusion criteria included being on rpm for at least 12 months and a patient of the practice for at least two years (12 months pre- and post-initiation of rpm).

this study included a retrospective analysis of data collected from subjects at a large outpatient pulmonology practice in the mid-atlantic region of the united states between may 2019 and february 2022. at this clinic, patients who were candidates for rpm had been offered voluntary participation in service tailored to chronic respiratory disease patients (spire health, san francisco, ca, usa). they continued regular follow-ups with their pulmonologists and received usual care according to the direction of their primary pulmonary physician for their copd. inclusion criteria for the present study included a clinical diagnosis of copd (copd, chronic bronchitis, obstructive lung/airways disease, or emphysema), subscribed to rpm for at least 12 months as of february 28, 2022, full electronic medical records (emr) at the site in question for one year before and one year after the start of rpm, and high healthcare utilization (≥1 er visit or hospitalization in the year prior to enrollment). all such patients were included in the analysis. the primary endpoint was unplanned, all-cause hospitalizations per subject. secondary endpoints included unplanned cardiopulmonary hospitalizations, respective lengths of stay, er visits, outpatient pulmonary visits, and systemic corticosteroid use, adherence to rpm, and time-to-visit (rpm escalation to provider visit).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of copd (copd, chronic bronchitis, obstructive lung/airways disease, or emphysema) * ≥1 hospitalization or emergency visit in the year prior to enrollment * enrolled in the spire rpm patient monitoring service for at least 12 months * a patient of the practice for at least two years (12 months pre- and 12 months post-initiation of rpm). exclusion criteria: * none

Keywords: acute exacerbation of copd hospitalization exacerbation remote patient monitoring copd
effect of melatonin on body composition, glucose metabolism and lipid metabolism

Conditions: Acanthosis Nigricans; Obesity

Summary: effect of melatonin on body composition, glucose metabolism and lipid metabolism.

the effect of melatonin on body composition, glucose metabolism and lipid metabolism in patient with obesity and acanthuses nigrican.

Eligibility criteria:
inclusion criteria: * age:18-60 years old; * bmi ≥ 28 kg/m2； * with acanthosis nigricans。 exclusion criteria: * with liver, kidney, gastrointestinal or other major organic serious diseases, cancer, lactating women, pregnancy.

Keywords: acanthosis nigricans obesity
detection of chlamydia trachomatis, neisseria gonorrhoeae and mycoplasma genitalium by real-time multiplex polymerase chain reaction (pcr) after pooling pharyngeal, anorectal and urinary samples

Conditions: Chlamydia Trachomatis Infection; Neisseria Gonorrheae Infection; Mycoplasma Genitalium Infection; Sensitivity; Polymerase Chain Reaction

Summary: this study aims to compare the sensitivity of detecting chlamydia trachomatis, neisseria gonorrhoeae and mycoplasma genitalium by real-time multiplex pcr in a pooled analysis (i.e. gathering pharyngeal, anorectal and urinary samples) versus the standard of care (where a real-time multiplex pcr is made in each of the three samples).

patients detected positive for one of the three (sexually transmitted infection)stis (chlamydia trachomatis, neisseria gonorrhoeae or mycoplasma genitalium) on one site will be re-sampled twice at each of the three sites (pharynx, rectum, urine) before receiving antibiotics. then, a real-time multiplex pcr will be performed on the pooled sample (merging pharyngeal, anorectal and urinary samples) versus on each of the three samples separately (i.e. standard of care) to compare both sensitivities.

Eligibility criteria:
inclusion criteria: * patient having provided a written consent; * patient age \> 18 years; * man who have sex with men tested positive for one the three stis : chlamydia trachomatis, neisseria gonorrhoeae or mycoplasma genitalium * covered by health insurance exclusion criteria: * being under tutorship * being deprived of liberty * patient who received antibiotic treatment prior to study inclusion and re-sampling

Keywords: pooled analysis sensitivity men who have sex with men
igf-i and free fatty acids isn glucose metabolism in acromegaly

Conditions: Acromegaly

Summary: background glucose metabolism abnormalities are frequent in acromegaly. insulin resistance (ir) correlates with the intensity of acromegaly and insulin-like growth factor-i (igf-i) correlates better with ir than growth hormone (gh). insulin secretion (is) is significantly reduced in hyperglycemic acromegalics as compared with those with normal glucose levels. is is independent of acromegaly intensity. the aim of this study is to show that in active acromegaly: 1) igf-i does not cause ir but is just a better marker of acromegaly intensity than gh; 2) high gh levels induce ir through free fatty acids (ffa); 3) hyperglycemia is caused by a defficient is on a background of ir. methods intensity of acromegaly will be assessed using serum levels of gh, igf-i and igf binding globulin-3. ir and is will be assessd using an intravenous glucose tolerance test acording to bergman model. ffa will be directly measured in plasma.


Eligibility criteria:
inclusion criteria: * active acromegaly based on following criteria: minimum gh in oral glucose tolerance test (ogtt) over 1 ng/ml and serum igf-i over upper limit of normal for age and sex * age between 18 and 65 years old exclusion criteria: * more than one previous pituitary surgical intervention for acromegaly * present medical treatment for acromegaly (somatostatin analogs, gh-receptor blockers, dopaminergic agonists) * previous pituitary radiotherapy * present medical treatment for hyperglycemia (oral antidiabetic drugs, insulin, etc) * pituitary failure, treated or not * medical or surgical conditions which, in the oppinion of the principal investigator, could impact on study results or patient's safety * fasting blood glucose over 200 mg/dl or hba1c over 8%. * body mass index less than 20 or over 35 kg/mp
identification of response to hypertonic dextrose prolotherapy markers in knee osteoarthritis patients by cytokine array

Conditions: Osteoarthritis, Knee

Summary: hypertonic dextrose prolotherapy has been used in knee osteoarthritis (oa) clinically for a long time. however the study about the mechanism is scant. the question of biomarkers of knee oa cartilage response to hypertonic dextrose prolotherapy remains currently unresolved. on this basis, the aim of this study was to characterize the secreted protein factors behind the inflammatory potential involving the hypertonic dextrose prolotherapy of knee oa. 10\~12 older than 65 years old knee oa patients will be recruited for clinical western ontario mcmaster university osteoarthritis (womac) index, knee x ray evaluation and knee joint synovial fluid analysis before and after hypertonic dextrose prolotherapy. the expressions of inflammatory factors will be measured by a novel cytokine antibody array methodology. the study will evaluate inflammation-related cytokines in patients of knee joint synovial fluid. human cytokine antibody array that allows profiling synovial fluid production of anti and pro-inflammatory cytokines simultaneously. altered levels of cytokine from the array membranes incubated with tissue lysates will quantitatively depict as a histogram for relative cytokine induction or reduction in the synovial fluid. the cytokines messenger ribonucleic acid levels will be quantified by quantitative reverse-transcription polymerase chain reaction and proteins expression was analyzed by enzyme-linked immunosorbent assay. the womac index, minimum joint space width, and human cytokine antibody array between before and after interventions will be compared. differences between groups will be determined by the mann-whitney u test. for the synovial angiogenesis is accompanied with inflammatory feature in knee oa, associations between endothelial growth factor (vegf) expression and vegf isoforms pattern will be determined with the spearman correlation.


Eligibility criteria:
inclusion criteria: * at least 6 months of symptomatic knee oa * clinical criteria of moderate or moderate to severe knee oa ( the american rheumatological association grade ii or iii) exclusion criteria: * severe knee oa (grade iv) * rheumatoid or other inflammatory arthritis * received physiotherapy, oral nsaids, corticosteroids or anticoagulant, during previous 2 weeks prior the treatment * received any knee intra-articular injections during previous one month prior the treatment * poorly controlled diabetes mellitus with fasting blood sugar greater than 200 mg/dl- * history of knee surgery * dementia or psychological disease.

Keywords: hypertonic dextrose prolotherapy osteoarthritis
correlation of weight loss with residual gastric volume and shape on computerized tomography in patients undergoing sleeve gastrectomy

Conditions: Weight Regain Post Bariatric Surgery

Summary: laparoscopic sleeve gastrectomy (lsg) has been accepted as a primary bariatric procedure. the aim of the study was to evaluate the volume and the morphologies of remnant stomachs after lsg and their association with weight loss

twenty patients who underwent laparoscopic sleeve gastrectomy (lsg) were followed prospectively and evaluated at 12 months after operation using computed tomography ct with 3d reconstruction to evaluate the shape and volume of the residual stomach after lsg. total sleeve volume (tsv), tube volume (tv), antral volume (av) and tube/antral volume ratio (tavr) were included.

Eligibility criteria:
inclusion criteria: * candidate for sleeve gastrectomy exclusion criteria: * revisional surgery

Keywords: shape, sleeve gastrectomy, inadequate weight loss, volumetry
reliability of topography measurements in keratoconus

Conditions: Keratoconus

Summary: the purpose of this study is to assess the reliability and repeatability of the parameters obtained using the galilei dual-scheimpflug corneal topographer for monitoring progression in eyes with keratoconus.

keratoconus is a progressive corneal degeneration characterized by progressive steepening and thinning of the central or paracentral cornea leading to corneal protrusion and resulting irregular astigmatism and high myopia. this disorder is usually bilateral and is linked to atopy and excessive eye rubbing, although the precise pathophysiology behind development of this condition is unclear. keratoconus is the most common corneal degeneration in the united states, affecting between 50 and 230 subjects per 100,000 population. early diagnosis and appropriate management of keratoconus relies greatly on accurate assessment of corneal topographic measurements. it is therefore imperative that the data obtained via corneal topography devices is accurate and reliable. the galilei dual scheimpflug analyzer integrates placido disc topography and dual scheimpflug tomography to assess anterior and posterior corneal curvature data. although there have been several studies performed assessing the ability of the galilei to accurately distinguish keratoconus from unaffected eyes and investigating interdevice reliability between the galilei analyzer and other tomographers, to our knowledge the repeatability of measurements obtained in this population via the galilei device has been incompletely evaluated to date. corneal topography data obtained via the galilei device is relied upon heavily in clinical decision making for keratoconic patients both in the hershey eye clinic and in a great number of ophthalmology practices world-wide. it is vital that the accuracy and repeatability of these measurements obtained via the galilei device are investigated. the primary endpoint to be measured in the study will be the maximum (steepest) and minimum (flattest) keratometry values in the central zone. secondary endpoints will be maximum keratometry across the entire area scanned, axis of corneal astigmatism, anterior and posterior best fit spheres in float mode with the diameter set to 8 mm, maximum anterior and posterior elevations, thinnest corneal thickness, and corneal asphericity at 6 mm, root mean square (rms) of the hoas, rms of the third-order coma, coma axis, vertical and horizontal coma and spherical aberration.

Eligibility criteria:
inclusion criteria: * patientswho are older than 18 years of age * patients who are scheduled to undergo galilei dual-scheimpflug corneal topography testing * patients who have been diagnosed with keratoconus * measurements with a reported reliability of 'good' from the topographer exclusion criteria: * patients who have undergone any prior surgical intervention involving the cornea (i.e. cornea transplant or intacs, or corneal cross linking)